Endoscopy 2019; 51(04): S60-S61
DOI: 10.1055/s-0039-1681348
ESGE Days 2019 oral presentations
Friday, April 5, 2019 14:30 – 16:30: EUS therapeutic pancreas South Hall 2B
Georg Thieme Verlag KG Stuttgart · New York

EUS-GUIDED, RFA ABLATION OF BENIGN AND MALIGNANT PANCREATIC NEOPLASMS AND EXTRA PANCREATIC METASTASIS IS FEASIBLE AND SAFE

A Dancour
1   Digestive Diseases Institute, Shaare Zedek Medical Center, Jerusalem, Israel
,
M Rottenstreich
1   Digestive Diseases Institute, Shaare Zedek Medical Center, Jerusalem, Israel
,
G Sheynkman
2   CT Institute, Shaare Zedek Medical Center, Jerusalem, Israel
,
E Tahover
3   Oncology Institute, Shaare Zedek Medical Center, Jerusalem, Israel
,
D Wengrower
1   Digestive Diseases Institute, Shaare Zedek Medical Center, Jerusalem, Israel
,
E Goldin
1   Digestive Diseases Institute, Shaare Zedek Medical Center, Jerusalem, Israel
,
T Golan
4   Pancreatic Cancer Center, Haim Sheba Medical Center, Tel Hashomer, Israel
,
D Livovsky
1   Digestive Diseases Institute, Shaare Zedek Medical Center, Jerusalem, Israel
› Author Affiliations
Further Information

Publication History

Publication Date:
18 March 2019 (online)

Also available at
 
 

    Aims:

    New therapeutic alternatives are needed for patients with pancreatic tumors not suitable for surgery or in order to avoid surgical morbidity. We present our data on the use of a new, through- the-echoendoscope radiofrequency ablation (RFA) device.

    Methods:

    A 150 cm, 19gauge needle-electrode (EUSRA- Taewoong medical) with RF delivery in the distal 10 mm, connected to a RF generator (VIVA RF STARmed, Korea) settled to deliver 50w was used.

    Results:

    Since March 2017, 22 patients (median age 63 (28 – 87)) with 36 lesions were treated: seven pancreatic malignant lesions (5 adenocarcinoma), sixteen benign pancreatic lesions (15 neuroendocrine), eight liver metastases, 4 lymph nodes and 1 retroperitoneal metastasis. The pancreatic lesions were located in head, neck, body, tail and uncinate process in 6, 1, 3, 3 and 5 patients. Median size of main lesion was 22 (7 – 55)mm. RFA was performed close to blood vessel or MPD in 7 and 10 times respectively without linked complication except for thrombosis of a small intrahepatic vein and mild delayed pancreatitis in 1 patient each. Other adverse events included: abdominal pain and intrahepatic bile duct stenosis in 2patients each. Median ablation number per lesion was 5 (1 – 16). Imaging showed complete or partial ablation in 15 and 7 patients respectively. After a median follow up of 6 (1 – 21) months no additional related complications were detected.

    Conclusions:

    EUS-guided RFA of pancreatic tumors and in chosen cases of extrapancreatic metastases is feasible and safe. It represents a promising alternative when surgery is not possible. Larger and longer studies are necessary.


    #